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Background: The international Innovative Medicines Initiative (IMI) project DRIVE-AB (Driving Reinvestment in Research
and Development and Responsible Antibiotic Use) aims to develop a global definition of ‘responsible’ antibiotic use.
Objectives: To identify consensually validated quantity metrics for antibiotic use in the outpatient setting.
Methods: First, outpatient quantity metrics (OQMs) were identified by a systematic search of literature and web
sites published until 12 December 2014. Identified OQMs were evaluated by a multidisciplinary, international
stakeholder panel using a RAND-modified Delphi procedure. Two online questionnaires and a face-to-face meet-
ing between them were conducted to assess OQM relevance for measuring the quantity of antibiotic use on a
nine-point Likert scale, to add comments or to propose new metrics.
Results: A total of 597 articles were screened, 177 studies met criteria for full-text screening and 138 were
finally included. Twenty different OQMs were identified and appraised by 23 stakeholders. During the first survey,
14 OQMs were excluded and 6 qualified for discussion. During the face-to-face meeting, 10 stakeholders
retained five OQMs and suggestions were made considering context and combination of metrics. The final set of
metrics included defined daily doses, treatments/courses and prescriptions per defined population, treatments/
courses and prescriptions per defined number of physician contacts and seasonal variation of total antibiotic use.
Conclusions: A small set of consensually validated metrics to assess the quantity of antibiotic use in the outpa-
tient setting was obtained, enabling (inter)national comparisons. The OQMs will help build a global conceptual
framework for responsible antibiotic use.
Introduction
Antibiotics are the cornerstone of the treatment of infectious dis-
eases, but bacterial resistance is a rapidly increasing global threat.
An important driver of resistance is antibiotic use.1–3 Accepted
antibiotic use metrics or units are needed for benchmarking and to
evaluate trends over time.4,5 Measuring the quantity of antibiotic
use is also crucial for designing antibiotic stewardship programmes
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and target setting by policy makers.5 In addition, it is a long-
standing goal to predict rates of resistance evolution and design
optimal treatment strategies accordingly.
Data on outpatient antibiotic use from the EU and countries
belonging to the European Economic Area/European Free Trade
Association are currently expressed as the number of defined daily
doses (DDDs) per 1000 inhabitants and per day; and the number of
packages per 1000 inhabitants and per day (PID), depending on
the availability of data on packages from the national surveillance
networks.6 In addition, many more different types of quantity
metrics have been used worldwide. The Innovative Medicines
Initiative (IMI) funded the international project DRIVE-AB (Driving
Reinvestment in Research and Development and Responsible
Antibiotic Use), which aimed to develop a global framework of
‘responsible’ antibiotic use (http://drive-ab.eu/).7 This study aimed
to identify consensually validated quantity metrics for antibiotic
use in the outpatient setting.
Materials and methods
We used a systematic literature and web site review followed by a RAND-
modified Delphi consensus procedure to develop and select in a multistep
approach a set of consensually validated outpatient quantity metrics
(OQMs)8 as described below. The systematic literature review is reported
according to the PRISMA statement.9
Systematic literature and web site search and
extraction of quantity metrics for antibiotic use
Search strategy
We first performed a systematic literature search using the MEDLINE data-
base to review the international literature for information about quantity
metrics for antibiotic use (articles published until 12 December 2014). The
search strategy combined three concepts: antibiotics; quantity metrics (split
into quantity and metric); and outpatient setting. An additional search
included articles that were neither included in the outpatient concept nor in
the inpatient concept search on quantity metrics. These articles were found
when using the combination of the outpatient and inpatient search on quan-
tity metrics (additional search; see Table S1 available as Supplementary data
at JAC Online). Finally, we performed a complementary search based on the
combined three concepts and outpatient setting on English web sites of rele-
vant organizations and institutions active within the field of antibiotic stew-
ardship (Table S2, available as Supplementary data at JAC Online).
Inclusion and exclusion criteria
The definition of a quantity metric we used was: ‘a measurable element
(generic metrics) of practice performance of the volume or cost of antibiotic
use whereby the outcome only gains value in its comparison’. An outpatient
was defined as a patient who is not hospitalized and visits a physician in the
ambulatory care setting. The definition included also ambulatory patients
visiting a physician based in a hospital, which is commonly seen in develop-
ing countries. We included studies on antibacterials for systemic use
(ATC J01)10 written in English. Papers without abstracts were included for
full-text screening if the title seemed relevant to our search. We excluded
publications about topical or vaginal use of antibiotics, antituberculosis
drugs, antimalarial antibiotics, antiviral drugs including anti-HIV drugs, anti-
helminthics, antifungals, anti-leprosy drugs and anti-Helicobacter drugs, as
well as interventional studies and studies concerning very limited patient
populations, e.g. cystic fibrosis patients. Finally, we excluded papers whose
full text could not be retrieved from any of the libraries of the centres partici-
pating in the study (eight different catalogues) or from Google ScholarV
R
.
Screening process, data collection and analysis
We searched for eligible papers, using the literature review management
software DistillerSRV
R
(Evidence Partners, Ottawa, Ontario, Canada). Two
researchers (A. V. and N. A.) independently performed the extraction of quan-
tity metrics from the selected literature and subsequently independently
examined the title and abstract of the publications to include any publication
potentially describing quantity metrics for antibiotic use in the outpatient set-
ting, for full-text screening. Articles were systematically included if there was
no abstract available, or if the abstract was insufficiently detailed to allow a
proper assessment of the eligibility criteria. We also searched the reference
list of each article for additional suitable studies. Discrepancies between the
results were discussed until consensus was reached.
During the ‘full screening’, we were specifically interested in papers that
included measurable elements (generic metrics) of the volume or cost of
antibiotic use, papers comparing different quantity metrics for antibiotic
use or that reported a correlation between quantity metric(s) and the selec-
tion or propagation of bacterial resistance as well as potentially unknown
quantity metrics for antibiotic use. Meaningful units were made with a
numerator and a denominator, where the numerator measures the
amount of antibiotic used and the denominator controls for the size of the
population studied. Use of antibiotics was defined as prescribing, buying,
dispensing, reimbursing and/or consuming of antibiotics.
The articles were categorized by publication year, whether it concerned
national, regional or international data, by socioeconomic setting (low- to
middle-income or high-income countries), by study type (prospective or ret-
rospective, cross-sectional or longitudinal), by data source (wholesale,
pharmacy, reimbursement, medical records or other), by type of numerator
(measurable unit) as well as denominator (population) used, and whether
the standardized WHO/ATC method of classification of antibacterials was
used.
All quantity metrics were discussed with the senior authors of this study.
Duplicate OQMs were deleted and those measuring similar outcomes were
grouped, removing overlaps.
RAND-modified Delphi procedure
The list of OQMs extracted from the literature was presented to a multidisci-
plinary stakeholder panel following the RAND-modified Delphi consensus
procedure.8,9 It consisted of two online surveys (first and second round)
with a face-to-face meeting between them to achieve consensus on a set
of key quantity metrics. Stakeholders having the following backgrounds
were selected: medical community (medical specialists and clinical phar-
macists); public health and patients; antibiotic research and development
(R&D); and payers, policy makers, governments and regulators (Table S3).
The selection process of the stakeholders is described elsewhere.11 All the
stakeholders consented to participate in the study and were aware that
their responses would be used for research purposes.
First questionnaire round
The literature-derived list of OQMs was presented to the stakeholder panel
using an internet-based SurveyMonkeyV
R
(Palo Alto, CA, USA) questionnaire
(Figure S1). The first round of the survey took place between August and
September 2015.
All stakeholders assessed each OQM on its relevance on a nine-point
Likert scale (1" clearly not relevant, 9" clearly relevant, plus a ‘cannot
assess’ option). Relevance was graded by the stakeholders in response to
the following question: ‘To what extent do you consider this OQM as a rele-
vant metric to measure quantity of antibiotic use in the outpatient setting?’.
Stakeholders could comment on proposed OQMs and could also add OQMs.
Relevance scores were calculated for each item.8 If the OQM had a
median7 and 70% of the stakeholders scored in the upper tertile, then
the OQM was marked as ‘accepted’. If the OQM had a median ,7 then the
OQM was marked as ‘not accepted’ and was excluded. If the OQM had a
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median7 and ,70% of the stakeholders scored in the upper tertile, then
the OQM was marked as ‘to be discussed’.
Consensus meeting
Stakeholders who participated in the first questionnaire round were invited
to a face-to-face consensus meeting on 30 September 2015. The results of
the analysis of the questionnaires were sent to the stakeholders in advance
of the consensus meeting. During the meeting, the stakeholders could
comment or rephrase OQMs with the label ‘to be discussed’ and discuss the
newly proposed OQMs.
Second questionnaire round
After the consensus meeting, all discussed, reformulated and added poten-
tial metrics were included in a second questionnaire. All stakeholders who
participated in the first round were asked whether they agreed (yes, no or
cannot assess) with the proposed OQMs and their definitions. For each
OQM, comments could be added.
Results
Literature search and extraction of quantity metrics for
antibiotic use
Out of 597 screened articles based on title and abstract, 138 studies
met the criteria for full-text screening. We added another 52 articles
through reference checking. Finally, we included 138 articles for
detailed review (Figure 1), of which 13 (9.4%) originated from low-
to middle-income countries, 42 (30.4%) concerned international
data and 49 (35.5%) national data. Thirty-five articles (25.4%)
reported the use of two or more metrics, 29 (21.0%) made a link
between antibiotic use and resistance and 5 (3.6%) reported the
relevance of OQMs for policy making. Figure 2 provides an overview
Total N references PubMed = 597
Outpatient search: N=551
Additional search*: N=41
Transfer inpatient team: N=5
Level 1 excluded references
from title and abstract
screening
N=388
Level 1 excluded references
low interest papers
N=71
Unable to obtain full text:
N=19
Excluded low interest
references: N=20
Excluded references
snowballing: N=13
Included references for detailed
review
N=(138)
Included publications
(references & websites) N=138
Excluded references
N=0
Level 2 full-text screening
N=138 (115 high interest + 23
conflicts)
References – snowballing
N=52
Web site references
N=0
Figure 1. Flowchart of included and excluded publications. *Additional search included articles that were included neither in the outpatient concept
nor in the inpatient concept search on quantity metrics.
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of the obtained OQMs based on the metric in the numerator.
The most frequently reported metric was based on the DDDs in the
numerator. Other reported metrics included metrics based on cost
calculations (tons or number of packages sold), proportions of con-
sultations or encounters for certain diagnoses [e.g. respiratory tract
infections, drug utilization 90%, or populations (e.g. children)].
Denominators were grouped into: (i) defined population; (ii) 100 per-
son-years; (iii) physician contacts; and (iv) km2 defined as the area
equal to a square of 1 km on each side. All reported metrics were
finally grouped into 20 different numerator–denominator combina-
tions for assessment during the first questionnaire round (Table 1).
These 20 OQMs were discussed with all researchers involved in this
study to make the definition more generic with respect to its
definition.
RAND-modified Delphi procedure
First questionnaire round
Out of 43 invited stakeholders, 23 (53%) completed the online sur-
vey, of whom 15 were based in Europe, 5 in North America, 2 in
Asia and 1 in Australia. Detailed information on the stakeholders’
backgrounds is described elsewhere.12
The first survey resulted in 0 ‘accepted’ OQMs and 14 OQMs were
excluded. Six OQMs qualified for discussion, meaning that the stake-
holders did not reach consensus on the relevance or non-relevance
of the items; and three new OQMs were suggested (Figure 2). These
nine OQMs were further discussed during the consensus meeting.
Consensus meeting
Ten stakeholders participated in the consensus meeting to discuss
the nine OQMs (morning session). Five OQMs were found relevant
without modification. The metric ‘individuals treated with antibiot-
ics per defined population’ was not retained due to its limited
added value with respect to DDDs, courses and prescriptions. Also,
the three suggested OQMs during the first round were not
retained. On the other hand, two supplementary metrics on sea-
sonal variation were added to the list of OQMs (Figure 2).
Consequently, seven OQMs were found relevant for assessment
during the second questionnaire round. During the discussion, sug-
gestions were made considering the context and combination of
metrics, especially that the DDD should be complemented with
another metric such as treatment, courses or prescriptions in the
numerator. When using the DDD, one should also only focus on
adults, excluding children because the DDD is based on the aver-
age adult dose used for the main indication and refers to the body
December 2014 – April 2015
Total N references reviewed=597 20 OQM assessed for their relevance
These were:
Defined Daily Dose (DDD) per
defined population
Treatment/courses per defined
population
Treatment/courses per defined
number of physician contacts
Prescriptions/defined population
Prescriptions/physician contacts
Individuals treated with antibiotics
per defined population
Average DDD per treatment course
N patients requiring second course
% patients completing AB course
+ 3 new OQM suggested:
- 14 OQM rejected (Median<7)
- 6 OQM disagreement (mean relevance
score ≥8; but <70% scores in top tertile
(7-9));
Included references detailed review = 138
Selection of antibiotic OQM (N=66 found)
were based on metric in numerator:
1)
2)
3)
4)
5)
6)
7)
8)
9)
Defined daily dose (N=21)
Packages (N=3)
Prescriptions (N=13)
Persons (N=4)
Other metrics (N=25)
Systematic review + complementary
web site search
Articles published until December 12, 2014
9-point Likert scale: scoring from “not
relevant=1” to “clearly relevant=9”
23 stake holders (response rate=53%)
June 2015
1st Delphi round 2nd Delphi round
Agreement with OQM
(Yes or no)
20 stake holders
(response rate=87%)
30 September 2015
9 OQM discussed
Selected
Rejected
20 different OQM identified
for assessment
+ 2 new OQM
suggested:
Selected (N=5)
Selected (N=1)
Rejected
7 OQM assessed for
agreement
Expert face to face
consensus meeting
N=7 stake holders
(response rate=30%)
December 2015
- Seasonal variation of
total antibiotic use
- Seasonal variation of
quinolone use
Figure 2. Results on OQMs of antibiotic use by RAND-modified Delphi procedure.
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weight of an adult of 70 kg.13 Finally, the choice of denominator
was discussed.
Second questionnaire round
The list of seven OQMs was sent to the complete stakeholder panel
(n"23). Twenty stakeholders returned the second questionnaire
(response rate 87%). Six OQMs were selected by .70% of the
panel members, including a new one that was suggested during
the consensus meeting (Figure 2).
The final set of outpatient quantity metrics is presented in Table
2. Details about the definitions used are presented in Table S4.
Discussion
In this study, we selected a set of six key generic quantity metrics
for measuring antibiotic use in the outpatient setting, based on sci-
entific literature and a web site search, while applying a systematic
RAND-modified Delphi procedure.
The first online survey round reached a response rate of 53%,
which is satisfactory because there are many challenges to con-
ducting surveys among physicians (and/or researchers), whose
response rates are in general lower than those of the general pop-
ulation.14 Our response rate was similar to the mean response rate
of 54% resulting from a review of 178 manuscripts published in
medical journals.15 The response rate of 87% for the second online
survey was very satisfactory. The number of stakeholders (10) par-
ticipating in the consensus meeting was within the range of 7–15
participants as recommended,8 large enough to permit diversity of
representation while still being small enough to allow everyone to
be involved in the group discussion of the proposed OQMs.
Diversity of expert panel members leads to consideration of differ-
ent perspectives and a wider range of alternatives.16 At the meet-
ing, important comments were made.
Most stakeholders emphasized the need to combine different
quantity metrics to optimize interpretation of the volumes of anti-
biotic use as each of the single metrics had some pitfalls in inter-
pretation. In particular, quantity metrics based on the Anatomical
Therapeutic Chemical (ATC) classification and the DDD measure-
ment unit10 were a point of discussion. Although the DDD is the
most commonly used numerator, the feasibility and usefulness of
this standardized metric strongly favours its complementation
with another metric such as treatments/courses or prescriptions
per defined population. We hypothesize that none of the metrics
from the review was accepted after the first round for this reason.
When using a combination of metrics, divergent trends in time
of antibiotic use may occur, depending on the metric used. This
was, for example, observed when comparing outpatient antibiotic
use expressed as the number of DDDs with the number of pack-
ages, treatments or insured individuals per 1000 inhabitants per
day. An increased trend of antibiotic use was observed when using
the metric based on the DDD in the numerator, while a decreased
trend in time was observed for the other metrics.17 It is very impor-
tant to clarify and understand the definition of the metric as con-
tradictory results may confuse policy makers, researchers and the
general public.17 Very often, the concept of a DDD is not well
understood. The DDD aims to capture the dosing regimen pre-
scribed to an adult 70 kg patient (single-unit dose, times a day and
the duration of the course), but this does not always reflect the
actual prescribed doses in some countries.18 Bruyndonckx et al.6
further showed that the average content of an antibiotic original
package in European countries has significantly increased over
time, with substantial differences between countries and antibiotic
subgroups, except for the quinolones. This finding had implications
in understanding associations between antibiotic use and resist-
ance, which also depended on the metric used. Inconsistent asso-
ciations and predictions of resistance were observed depending on
whether antibiotic use was expressed as ‘defined daily doses per
1000 inhabitants per day (DID)’ or ‘packages per 1000 inhabitants
per day (PID)’.19 The authors concluded that for this reason both
metrics, DID and PID, should be used for a better understanding
and interpretation of outpatient antibiotic use and its relation to
resistance.
Although the two metrics DID and PID are jointly reported by
ESAC-Net,20,21 the metric PID, based on packages, was rejected
during the first questionnaire round. Instead, prescriptions and
treatments (also defined as an antibiotic course with undefined
length of intake) in the numerator were put forward, which can be
considered as a good proxy for packages.17 While DDD and pack-
ages in general originate from wholesale data, the source of pre-
scription data is pharmacies, whereas treatment/courses data
originate from medical charts. For monitoring antibiotic use, coun-
tries will need to choose the appropriate metric depending on the
availability of data, but also on national legal provisions for the pre-
scription. It is, for example, inappropriate to use a metric based on
packages if antibiotics are dispensed by individual blister, single-pill
items or reconstituted packs. This is the case in the Netherlands,
the UK and Ireland.22 Table 2 further describes the advantages
Table 1. Proposed set of 20 outpatient quantity metrics presented to
stakeholders for assessment during the first questionnaire round
Metric
number Proposed metric
1 Defined daily doses per defined population
2 Defined daily doses per 100 person-years
3 Defined daily doses per defined number of physician contacts
4 Defined daily doses per km2
5 Treatments/courses per defined population
6 Treatments/courses per defined number of physician contacts
7 Standard units per defined population
8 Packages per defined population
9 Packages per defined number of physician contacts
10 Prescriptions per defined population
11 Prescriptions per 100 person-years
12 Prescriptions per defined number of physician contacts
13 Individuals treated with antibiotics per defined population
14 Individuals treated with antibiotics per 100 person-years
15 Individuals treated with antibiotics per defined number
of physician contacts
16 Kilograms per defined population
17 Antibiotic cost per defined population
18 Average daily quantities per defined population
19 Percentage of antibiotics per total drug use
20 Number of types of antibiotic prescribed in each
patient visit
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Table 2. Final set of quantity metrics for the outpatient setting (OQMs), their advantages and disadvantages of use
Outpatient quantity metric Advantages Disadvantages
OQM 1 DDDs per defined
population
Standardized tool for drug utilization research allow-
ing presentation, comparison and benchmarking of
drug consumption statistics at international and
other levels.
The DDD provides a fixed unit of measurement
independent of price and dosage form and is
not suitable for guiding decisions about reim-
bursement, pricing and therapeutic substitution.
The DDD is a unit of measurement and does not
necessarily reflect the recommended or pre-
scribed daily dose.
The DDD gives a rough estimate of consumption
and not an exact picture of actual use.
Not suitable for measuring consumption among
children and neonates because the DDD reflects
the assumed average maintenance dose per
day for a drug used for its main indication in
adults.
DDDs are only assigned for drugs that already
have an ATC code; a local DDD may be used or
its use might be omitted.
The WHO Collaborating Centre for Drug Statistics
Methodology occasionally updates the DDD
value for a drug, which might introduce a bias
when comparing between years, unless the
DDDs are retrospectively corrected.
Recommended to be used in combination with
OQMs 2–5
OQM 2 Treatments/courses per
defined population
Counts number of treatments independent of the
prescribed doses.
Does not take into account prescribed doses (daily
dose and duration of the antibiotic course).
Good proxy for packages. If obtained from medical charts, this OQM might
overestimate antibiotic use depending on the
number of patients not collecting their antibiotic
at the pharmacy.
OQM 3 Treatments/courses per
defined number of
physician contacts
Counts number of treatments independently of the
prescribed doses.
Does not take into account prescribed doses (daily
dose and duration of the antibiotic course).
Good proxy for packages. The denominator allows comparison or bench-
marking ‘within countries only’.
If obtained from medical charts, this OQM might
overestimate antibiotic use depending on the
number of patients not collecting their antibiotic
at the pharmacy.
OQM 4 Prescriptions per defined
population
Counts number of treatments independently of the
prescribed doses.
Does not take into account prescribed doses (daily
dose and duration of the antibiotic course).
Good proxy for packages. If obtained from pharmacy data and counting
only the prescriptions, this OQM may underesti-
mate antibiotic use depending on the preva-
lence rate of OTC antibiotic use.
OQM 5 Prescriptions per defined
number of physician
contacts
Counts number of treatments independently of the
prescribed doses.
Does not take into account prescribed doses (daily
dose and duration of the antibiotic course).
Good proxy for packages. The denominator allows comparison or bench-
marking ‘within countries only’.
If obtained from pharmacy data and counting
only the prescriptions, this OQM may underesti-
mate antibiotic use depending on the preva-
lence rate of OTC antibiotic use.
Continued
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and disadvantages of each OQM. It may help researchers to cor-
rectly decide which OQM to use and should be adapted to their
country or local setting of interest.
The definition of the denominator was also discussed during
the consensus meeting. ‘Defined number of physician contacts’ as
denominator was considered as an unstable denominator that
can change over time and might differ a lot between countries
depending on local policies and structures. It was concluded by
the stakeholders that the two metrics based on this denominator
(treatment/courses and prescriptions per defined number of physi-
cian contacts) are only useful to compare rates within countries
and not to compare or benchmark between countries. Very differ-
ent kinds of data sources providing denominator data exist.
Besides the commonly used WHO mid-year population, covering
the whole population,23 reimbursement data might provide less
coverage depending on the proportion of citizens covered by the
insurance.4 The choice of the denominator has implications for the
estimation of overall antibiotic use, which might be underesti-
mated for countries using reimbursement data where there is a
high prevalence of over-the-counter (OTC) use of antibiotics.
Wholesale data, on the other hand, might include export of antibi-
otics to other countries and this could overestimate overall antibi-
otic use.24
Finally, the metric ‘seasonal variation of total antibiotic use’
(defined as the use of antibiotics in certain periods in a year com-
pared with other periods in a year, marked by specific weather con-
ditions, temperatures or length of day) was added during the
consensus meeting and was accepted during the second question-
naire round. Use of antibiotics is herewith expressed as a propor-
tion, most of the time a percentage (Table S4), independently of
the kind of numerator measuring the amount of antibiotics used.
During the discussion, the issue was raised whether this metric
could be considered as a ‘quality indicator’. In this study we
defined a quantity metric as a measure that reflects the volume or
the costs of antibiotic use, whereas a quality indicator reflects the
degree to which an antibiotic prescription is correct or appropriate.
Despite their different definition, some overlap or interpretation
seemed possible. Consequently, seasonal variation was consid-
ered as a quantity metric. Despite lack of evidence, this metric
might be a surrogate marker for quality of prescription, since over-
prescription in the winter might possibly be the result of unneces-
sary antibiotic use for viral infections.
The strength of our study is found in our panel of 23 multidisci-
plinary members from around the world having ample experi-
ence in antibiotic stewardship, ensuring optimal measurement of
the list of OQMs (face validity). The global background of the
panel may encourage transferability to all continents. The
stakeholders brought expertise from various fields, such as infec-
tious disease control, policy making, public health administration,
contingency planning and public health nursing, and had been
involved in regional and national meetings on the subject. Our
key OQMs were selected to combine evidence- and consensus-
based OQMs, with a strong evidence-based development method
as recommended.25
A limitation of our study is that we only searched the MEDLINE
database for our literature review. We also screened relevant web
sites and the reference lists of all included articles. However, this
did not result in the inclusion of supplementary references.
Importantly, the list of OQMs is merely based on practice and
expert opinion. Expert opinion is considered to be the least valuable
form of evidence.26 Our set of OQMs, however, could be the start-
ing point for methodologically sound empirical studies.
Conclusions
It is crucial to use a robust quantity metric enabling (inter)national
benchmarking and stability over time to ensure stable longitudinal
trends of antibiotic use. We present a small set of consensually
validated quantity metrics assessing the quantity of antibiotic use
in the outpatient setting. The OQMs will help build an international
conceptual framework on responsible antibiotic use.
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